A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

Conditions

• Palmoplantar Pustulosis

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Bimekizumab — DRUG
  Study participants will receive bimekizumab at pre-specified time points.
• Placebo — DRUG
  Study participants will receive matching placebo at pre-specified time points.

Study Details

The purpose of this study is to evaluate the efficacy and safety of bimekizumab compared with placebo in participants with palmoplantar pustulosis (PPP).

Key Dates

First listed

Oct 21, 2025

Start date

Nov 14, 2025

Status verified

Aug 2026

Primary completion

Dec 27, 2027

Completion

Nov 22, 2029

Study Design

Enrollment

320 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Bimekizumab
  Subjects randomized to this arm will receive the bimekizumab dosing regimen for the entire duration of the study.
• Placebo Comparator: Placebo
  Subjects randomized to this arm will receive placebo during the initial treatment period before transitioning to bimekizumab in the maintenance treatment period.

Primary Outcome Measure

Palmoplantar pustulosis-Investigator Global Assessment 0/1 (PPP-IGA 0/1) response at Week 16 [ Time Frame: At Week 16 ]

Central Contacts

• UCB Cares
  +18445992273
  [email protected]

Locations (8)

Find similar trials in Birmingham, AL

Related Studies

• A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
  PHASE2 · Recruiting · LEO Pharma · Fountain Valley, California